Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more
Cidara Therapeutics Inc (CDTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.096x
Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has a cash flow conversion efficiency ratio of -0.096x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.62 Million) by net assets ($422.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cidara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cidara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cidara Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirae Asset Daewoo Co Ltd Pref
KO:00680K
|
-0.338x |
|
AAON INC. DL-004
F:AAO
|
N/A |
|
Infratil Ltd
AU:IFT
|
0.004x |
|
Plexus Corp
NASDAQ:PLXS
|
-0.010x |
|
TIANQI LITHIUM H YC 1
F:2220
|
N/A |
|
JB Hi-Fi Ltd
AU:JBH
|
0.035x |
|
Vibra Energia S.A.
SA:VBBR3
|
0.136x |
|
Chang Hwa Commercial Bank Ltd
TW:2801
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cidara Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $163.31 Million | $-176.53 Million | -1.081x | -139.56% |
| 2023-12-31 | $-8.21 Million | $-22.43 Million | 2.732x | +38.55% |
| 2022-12-31 | $-14.44 Million | $-28.47 Million | 1.972x | +268.61% |
| 2021-12-31 | $21.57 Million | $-25.23 Million | -1.170x | +76.97% |
| 2020-12-31 | $10.71 Million | $-54.41 Million | -5.078x | -573.37% |
| 2019-12-31 | $37.84 Million | $-28.53 Million | -0.754x | +21.35% |
| 2018-12-31 | $59.14 Million | $-56.70 Million | -0.959x | -14.78% |
| 2017-12-31 | $59.74 Million | $-49.91 Million | -0.835x | -85.22% |
| 2016-12-31 | $88.18 Million | $-39.77 Million | -0.451x | -80.54% |
| 2015-12-31 | $103.91 Million | $-25.96 Million | -0.250x | +31.62% |
| 2014-12-31 | $21.10 Million | $-7.71 Million | -0.365x | -148.74% |
| 2013-12-31 | $-1.40 Million | $-1.05 Million | 0.750x | -- |